|
研究摘要
Peritoneal metastasis as a result of the dissemination of gastrointestinal or gynecological cancer into the peritoneal cavity and often associated with disease progression and poor prognosis. At the Ninth International Congress on Peritoneal Surface Malignancies held in Amsterdam, the Netherlands, 2014, the Peritoneal Surface Oncology Group International officially proposed the International Recommendations for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) as the standard treatment for appendiceal mucinous cancer, colorectal peritoneal metastasis, and malignant peritoneal mesothelioma, and it is a recommended therapy for ovarian cancer and gastric cancer with peritoneal metastasis. Unfortunately, among the peritoneal metastasis derived from different gastrointestinal cancers, gastric cancer peritoneal metastasis had the lowest 5-years survival rate following CRS/HIPEC. Therefore, it is necessary to carry out a strictly designed prospective clinical study on gastric cancer peritoneal metastasis to improve the treatment strategy and efficacy and to promote the comprehensive treatment approach in clinical oncology.
|